INCYTE CORP cotiza a 112.72 USD y tiene una capitalización bursátil de $22.8B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICL…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $3.09 | $1.81 | $1.80 |
| Estimado | $-3.67 | $2.15 | $1.34 | $1.92 |
| Sorpresa | — | +43.7% | +35.1% | -6.2% |
| Métrica | INCY | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 92.8% | 57.0% | +35.7% |
| Operating Margin | 29.5% | -38.6% | +68.1% |
| Net Margin | 25.0% | -33.6% | +58.6% |
| FCF Margin | — | -13.9% | — |
| ROE | 24.9% | -40.4% | +65.3% |
| ROA | 18.5% | -32.0% | +50.5% |
| Current Ratio | 3.32 | 2.84 | +0.48 |
| Debt / Equity | — | 0.28 | — |